Huseyin Albus Kilili

Mr. Huseyin Albus Kilili

Milner Centre for Evolution, Bath, Bath and North East Somerset, UK
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADAlberto D'Angelo
Alberto D'Angelo
HKHuseyin Albus Kilili
Huseyin Albus Kilili
RCRobert Chapman
Robert Chapman
DGDaniele Generali
Daniele Generali
ITIngeborg Tinhofer
Ingeborg Tinhofer
AUAraxi O Urrutia
Araxi O Urrutia
The immune system plays a central role in the onset and progression of cancer. A better understanding of transcriptional changes in immune cell-related genes associated with cancer progression, and their significance in disease prognosis, is therefore needed. NanoString-based targeted gene expression profiling has advantages for deployment in a clinical setting over RNA-seq technologies. We analysed NanoString PanCancer Immune Profiling panel gene expression data encompassing 770 genes, and overall survival data, from multiple previous studies covering 10 different cancer types, including solid and blood malignancies, across 515 patients. This analysis revealed an immune gene signature comprising 39 genes that were upregulated in those patients with shorter overall survival; of these 39 genes, three (MAGEC2, SSX1 and ULBP2) were common to both solid and blood malignancies. Most of the genes identified have previously been reported as relevant in one or more cancer types. Using Cibersort, we investigated immune cell levels within individual cancer types and across groups of cancers, as well as in shorter and longer overall survival groups. Patients with shorter survival had a higher proportion of M2 macrophages and γδ T cells. Patients with longer overall survival had a higher proportion of CD8+ T cells, CD4+ T memory cells, NK cells and, unexpectedly, T regulatory cells. Using a transcriptomics platform with certain advantages for deployment in a clinical setting, our multi-cancer meta-analysis of immune gene expression and overall survival data has identified a specific transcriptional profile associated with poor overall survival.

24 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
BPBenjamin Padilla-Morales
Benjamin Padilla-Morales
AAAlin P. Acuña-Alonzo
Alin P. Acuña-Alonzo
HKHuseyin Albus Kilili
Huseyin Albus Kilili
ACAtahualpa Castillo-Morales
Atahualpa Castillo-Morales
KDKarina Díaz-Barba
Karina Díaz-Barba
AUAraxi O. Urrutia
Araxi O. Urrutia
In mammals, sexual size dimorphism often reflects the intensity of sexual selection, yet its connection to genomic evolution remains unexplored. Gene family size evolution can reflect shifts in the relative importance of different molecular functions. Here, we investigate the associate between brain development gene repertoire to sexual size dimorphism using 124 mammalian species. We reveal significant changes in gene family size associations with sexual size dimorphism. High levels of dimorphism correlate with an expansion of gene families enriched in olfactory sensory perception and a contraction of gene families associated with brain development functions, many of which exhibited particularly high expression in the human adult brain. These findings suggest a relationship between intense sexual selection and alterations in gene family size. These insights illustrate the complex interplay between sexual dimorphism, gene family size evolution, and their roles in mammalian brain development and function, offering a valuable understanding of mammalian genome evolution.

Verified
Journal Article
Open access
PDF file
ADAlberto D'Angelo
Alberto D'Angelo
FGFabiola Giudici
Fabiola Giudici
RCRobert Chapman
Robert Chapman
JDJacob Darlow
Jacob Darlow
HKHuseyin Albus Kilili
Huseyin Albus Kilili
Daniele GeneraliDaniele Generali
Daniele Generali
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6 i), abemaciclib, palbociclib, and ribociclib, have been FDA-approved for the treatment of hormone receptor-positive (HR+), HER2−negative (HER2−) advanced breast cancer (aBC). This targeted therapy has revived hope in those aBC patients who did not respond to standard therapies. Interestingly, when administered as a single agent, CDK4/6 modulated several peripheral blood cells after a short-course treatment of 28 days. However, the impact of these immune effects has yet to be thoroughly investigated. Methods: We administered abemaciclib, palbociclib, and ribociclib monotherapy to 23 patients with HR+/HER2− metastatic breast cancer. The aim is to investigate the impact of on-treatment modifications on peripheral blood cells and their composite scores in patients after a 28-day course of CDK4/6 i alone. Results: In the current study, we observed a significant decrease in neutrophils (p-value < 0.001) for patients treated with abemaciclib, palbociclib, and ribociclib. An overall decrease of Tregs was observed and potentially linked to palbociclib treatment. The neutrophile to lymphocyte (N/L) ratio was also decreased overall and potentially linked to abemaciclib and palbociclib treatment. Platelets were decreased in patients administered with abemaciclib. Notably, the radiometabolic response was available only for those patients treated with ribociclib and abemaciclib, and only those lesions treated with ribociclib reached statistical relevance. Conclusions: Our study strongly supports the notion that CDK4/6 inhibitors induce tumour immune modulation. N/L ratio and platelet levels decreased due to treatment. Future studies should test whether patients would benefit from immunomodulators in association with CDK4/6 agents in a larger clinical trial. Moreover, the CDK4/6-induced immune modulation could also be considered a potential predictive clinical factor in HR+/HER2− advanced breast cancer.

25 August 2023
Verified
Preprint
Open access
PDF file
BPBenjamin Padilla-Morales
Benjamin Padilla-Morales
KDKatie Davis
Katie Davis
CBChloe Barnes
Chloe Barnes
AMAldo Carillo Muñoz
Aldo Carillo Muñoz
OGOscar García-Miranda
Oscar García-Miranda
AUAraxi Urrutia
Araxi Urrutia
Sexual selection has long been thought to promote speciation, but evidence is inconclusive. In Odonata - which includes dragonflies and damselflies-, wing pigmentation has been found to be influenced by sexual selection. Past evidence shows that wing pigmentation in males is a driver of speciation in damselflies. However, whether sexual dimorphism per se is associated with species diversification rates has not been tested. Here we test whether wing pigmentation sexual dimorphism influences diversification rates in a supertree of 1,239 species, the most comprehensive phylogeny inferred for the group. We find that wing pigmentation among dimorphic males is associated with higher species diversification rates in damselflies but not in dragonflies. This study presents the first evidence of the role of species sexual dimorphism in species diversification in a clade identified as a marker of habitat quality. In the face of accelerating biodiversity loss, uncovering diversification drivers is of pressing importance.